Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: Results from the Anemia Cancer Treatment (ACT) study

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1714-1721

  Aapro, M ^a   Ludwig, H ^b   Bokemeyer, C ^c   MacDonald, K ^d   Soubeyran, P ^e   Turner, M ^f   Albrecht, T ^d,g   Abraham, I ^d,h,i  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b WILHELMINEN HOSPITAL   (Austria)

^c UNIVERSITY OF HAMBURG   (Germany)

^d Matrix45 ^*  (United States)

^e INSTITUT BERGONIÉ   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g UNIVERSITY OF VIRGINIA   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ Division of Plant Pathology and Microbiology   (United States)

Author keywords

Anemia; Erythropoietin; Hemoglobin; Modeling; Outcomes; Treatment response

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG RESPONSE; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ASIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; GEOGRAPHY; GUIDELINE ADHERENCE; HEMATINICS; HEMOGLOBINS; HUMANS; LATIN AMERICA; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70349639241     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp063     Document Type: Article

References (30)

1. Anonymous. Erythropoietin analogues: An unnecessary class of drugs. Lancet Oncol 2008; 9: 81.
2. Aapro MS, Birgegård G, Bokemeyer C et al. Erythropoietins should be used according to guidelines. Lancet Oncol 2008; 9: 412-413.
3. Nowrousian M, Dunst J, Vaupel P. Erythropoietin-stimulating agents: favorable safety profile when used as indicated. Strahlenther Onkol 2008; 184: 121-126.
4. Blohmer JU, Dunst J, Harrison L et al. Cancer-related anemia: Biological findings, clinical implications and impact on quality of life. Oncology 2005; 68 (Suppl 1): 12-21.
5. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001; 91: 2214-2221.
6. Nissenson AR, Goodnough LT, Dubois RW. Anemia: Not just an innocent bystander? Arch Intern Med 2003; 163: 1400-1404.
7. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998; 25: 43-46.
8. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201-2216.
9. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270.
10. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13: 33-36.
11. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-4107.
12. Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26: 132-149.
13. Mikhael J, Melosky B, Cripps C et al. Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol 2007; 14: 209-217.
14. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
15. Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of cancer-related anemia in Europe: Findings from the Anemia Cancer Treatment (A.C.T.) study. Eur J Cancer in press doi: 10.1016/j.ejca.2009.02.003.
16. Aapro M, Van Erps J, MacDonald K et al. Managing cancer-related anemia in congruence with the EORTC guidelines is an independent predictor of hemoglobin outcome: Initial evidence from the RESPOND study. Eur J Cancer 2009; 45: 8-11.
17. Aapro M, Abraham I, Bokemeyer C et al. The background and methodology of the Anaemia Cancer Treatment (A.C.T.) survey: A retrospective study of practice patterns and outcomes in the management of anemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer 2008; 16: 193-200.
18. Guardiola E, Morschhauser F, Zambrowski JJ et al. Prise en charge de l'anémie chez les patients préesentant une pathologie maligne: résultats de l'étude F-ACT (French Anaemia Cancer Treatment) [Management of anaemia in patients with cancer: Results of the F-ACT study (French Anaemia Cancer Treatment)]. Bull Cancer 2007; 94: 907-914.
19. Ludwig H, Fritz E, Leitgeb C et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-1063.
20. Cazzola M, Ponchio L, de Benedetti F et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996; 87: 4824-4830.
21. Beguin Y. A risk-benefit assessment of epoetin in the management of anemia associated with cancer. Drug Saf 1998; 19: 269-282.
22. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-3425.
23. Thatcher N. Predicting the response to r-HuEPO in anaemic cancer patients undergoing chemotherapy. Erythropoiesis: New Dimensions in the Treatment of Anaemia 1995; 6: 99-106.
24. Henry DH, Glaspy J. Predicting response to epoetin alfa in anemic cancer patients receiving chemorx. Proc Am Soc Clin Oncol 1997; 16: 49a.
25. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 2003; 8: 99-107.
26. Stasi R, Amadori S, Littlewood TJ et al. Management of cancer-related anemia with erythropoietic agents: Doubts, certainties, and concerns. Oncologist 2005; 10: 539-554.
27. Dranitsaris G, Clemons M, Verma S et al. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: Development of a prediction model. Lancet Oncol 2005; 6: 856-863.
28. Ray-Coquard I, Le Cesne A, Rubio MT et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999; 17: 2840-2846.
29. Timmermans S, Mauck A. The promises and pitfalls of evidence-based medicine. Health Aff 2005; 24: 18-28.
30. Smith TJ, Hillner BE. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 2001; 19: 2886-2897.